Tissue and Disease Modeling Core

The Tissue and Disease Modelling Core (TDMC) at the BC Children’s Hospital Research Institute (BCCHRI) offers: 1) rapid generation of induced pluripotent cells (iPSCs) from patient blood samples; and editing of the genome of these iPSCs. This facility also offers training to users on: 1) the proper culture of pluripotent cells and 2) their differentiation towards various lineages.

The TDMC enables researchers to access powerful iPSC and genome editing technology to; 1) determine the biological mechanisms of disease in patients, and 2) use disease models, built from patient cells, to inform diagnosis and therapeutic strategies. 

No other service of this kind, offering access to this cutting-edge technology, is being offered in Western Canada.

Dr. Francis Lynn, oversees the scientific and technical operations of the TDMC, and he has proven expertise in iPSC and genome editing technology. To date, Dr. Lynn has facilitated genome-editing projects underway in the Departments of Pediatrics, Biochemistry, and Pathology and Laboratory Medicine, and at the Centres for Brain Health and Heart Lung Innovation, as well as the Pancreas Centre BC. 

Generous support from UBC's Faculty of Medicine is enabling expansion of the facility so that it can accommodate projects from researchers across the whole of the Faculty of the Medicine (FOM). This funding also allows a 10% discount to base costing for FOM-led projects.

Basic iPSC Service

Within 3 months the TDMC can generate at least 3 iPSC clones from PBMCs (~0.5ml of blood). These lines will be SeV free and characterized with Nanog, SSEA, and Tra-1-60. They will also have a normal karyotype at commonly mutated loci. 

Base costing for generating 3 iPSC lines for academic programs is $2,000.

BCCHRI & FOM researchers get a 10% discount.

Contact Jeffrey Helm (jhelm@mail.ubc.ca, 604-875-2000 x7954) to discuss your project and develop a Statement of Work.

Genomic Editing Service

Genome Editing (CRISPR/Cas) projects are also accepted: 

For transfection of CRISPR/Cas vector, sorting, picking colonies, and freezing down cell aliquots the timeline is 30 days with a base cost for academic programs of $1,000.

Genome editing vectors can be produced by the facility within 7 days, with a base cost of $500 for academic programs.

Consulting from Dr. Lynn on vector development is also available at a base cost of $100/hr for academic programs.

BCCHRI & FOM researchers get a 10% discount.

Contact Jeffrey Helm (jhelm@mail.ubc.ca, 604-875-2000 x7954) to discuss your project and develop a Statement of Work.

Other Terms and Conditions

Assumptions:

If the induced pluripotent cell production service is provided, the TDMC is responsible for providing viable induced pluripotent cells from human PBMCs with the assumption that the starting PBMC sample is viable and of good quality.  In addition, the TDMC is not responsible for cell quality or transport of samples both to and from the TDMC labs. It is the responsibility of each client to ensure appropriate transfer of samples and cells.

If Genome Editing services are provided, the TDMC is not responsible for the effectiveness of the vector used. If TDMC personnel are involved in the vector design process, they will provide expert advice, but the efficacy of any vector used for CRISPR/Cas genome editing is not known until the entire process in completed. Thus, clients are paying for expert TDMC personnel to go through the process, but the results are not guaranteed.

Change Management Process:

The delivery schedule for each service/process is an estimation. It is possible that the timeline will be extended due to unforeseen circumstances. There will be no additional cost recovery for timeline changes due to TDMC personnel error. Timeline extensions not due to TDMC error will be tracked and cost recovery only initiated to cover costs incurred after a 100% increase in the timeline of the entire project.

Ownership:

It is the responsibility of the client to ensure that they have informed consent and ethics in place for generating and using IPSCs from patient blood or fibroblasts. Once generated and received by the client cell lines are property of the client, not the TDMC. The TDMC will keep limited frozen backups of cells for 12 months. Longer-term storage of cells can be done through the BCCHRI Biobank.